Clinical Trial Update: Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating brigatinib in ALK-positive non-small cell lung cancer identified via blood-based assays.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: JI-YOUN HAN | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN